Methamphetamine-induced deficits of brain monoaminergic neuronal markers: Distal axotomy or neuronal plasticity

Neuroscience

Volumn 122, Issue 2, 2003, Pages 499-513

  Guilarte, T R ^a   Nihei, M K ^a   McGlothan, J L ^a   Howard, A S ^a  

^a The Johns Hopkins University   (United States)

Author keywords

Glial cells; Methamphetamine; Monoaminergic markers; Neurodegeneration; Peripheral benzodiazepine receptor; Rat brain

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; BIOLOGICAL MARKER; BRAIN MONOAMINE; CARRIER PROTEIN; DOPAMINE; DOPAMINE TRANSPORTER; MEMBRANE PROTEIN; METHAMPHETAMINE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; PAROXETINE; SEROTONIN; SEROTONIN TRANSPORTER; TRITIUM; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER TYPE 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTOSIS; BODY WEIGHT; BRAIN; BRAIN INJURY; BRAIN REGION; CELL ACTIVATION; CENTRAL GRAY MATTER; CONTROLLED STUDY; CORPUS STRIATUM; DRUG PROTEIN BINDING; GLIA CELL; HYPERTHERMIA; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; MONOAMINERGIC SYSTEM; NERVE CELL PLASTICITY; NERVE FIBER TRANSECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0242403117     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(03)00476-7     Document Type: Article

References (84)

1. Axt K.J., Molliver M.E. Immunocytochemical evidence for methamphetamine-induced serotonergic axon loss in the rat brain. Synapse. 9:1991;302-313.
2. Bandler R. Induction of "rage" following microinjection of glutamate into midbrain but not hypothalamus of cats. Neurosci Lett. 30:1982;183-188.
3. Berman S.B., Zigmond M.J., Hastings T.G. Modifications of dopamine transporter functions effect of reactive oxygen species and dopamine . J Neurochem. 67:1996;593-600.
4. Bowyer J.F., Davies D.L., Schmued L., Broening H.W., Newport G.D., Slikker J.W., Holson R.R. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharm Exp Ther. 268:1994;1571-1580.
5. Bowyer J.F., Holson R.R. Methamphetamine and amphetamine neurotoxicity. Chang L.W., Dyer R.S. Handbook of neurotoxicology. 1995;845-870 Marcel Dekke, Inc, New York.
6. Bowyer J.F., Clausing P., Schnued L., Davies D.L., Binienda Z., Newport G.D., Scallet A.C., Slikker W. Parentally administered 3-nitropropionic acid and methamphetamine can combine to produce damage to terminals and cell bodies in the striatum. Brain Res. 712:1996;221-229.
7. Bowyer J.F., Frame L.T., Clausing P., Nagamoto-Combs K., Osterhout C.A., Sterling C.R., Tank W. Long-term effects of amphetamine neurotoxicity on tyrosine hydroxylase mRNA and protein in aged rats. J Pharm Exp Ther. 286:1998;1074-1085.
8. Broening H.W., Pu C., Vorhees C.V. Methamphetamine selectively damages dopaminergic innervation to the nucleus accumbens core while sparing the shell. Synapse. 27:1997;153-160.
9. Brunswick D.J., Benmansour S., Tejani-Butt S.M., Hauptmann M. Effects of high-dose methamphetamine on monoamine uptake sites in rat brain measured by quantitative autoradiography. Synapse. 11:1992;287-293.
10. Cappon G.D., Pu C., Vorhees C.V. Time-course of methamphetamine-induced neurotoxicity in rat caudate-putamen after single-dose treatment. Brain Res. 863:2000;106-111.
11. Cass W.A. Attenuation and recovery of evoked overflow of striatal serotonin in rats treated with neurotoxic doses of methamphetamine. J Neurochem. 74:2000;1079-1085.
12. Cass W.A., Manning M.W. Recovery of presynaptic dopaminergic functioning in rats treated with neurotoxic doses of methamphetamine. J Neurosci. 19:1999;7653-7660.
13. Cubells J.F., Rayport S., Rajendran G., Sulzer D. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J Neurosci. 14:1994;2260-2271.
14. Daniels G.M., Amara S.G. Regulated trafficking of the human dopamine transporter. J Biol Chem. 274:1999;35794-35801.
15. Deakin J.F.W., Dostrovsky J.A. Involvement of the periaqueductal grey matter and spinal 5-hydroxytryptaminergic pathways in morphine analgesia effects of lesions and 5-hydroxytryptamine depletion . Br J Pharmacol. 63:1978;159-165.
16. Eisch A.J., Gaffney M., Weihmuller F.B., O'Dell S.J., Marshall J.F. Striatal subregions are differentially vulnerable to the neurotoxic effects of methamphetamine. Brain Res. 598:1992;321-326.
17. Finley J.C.W., Lindstrom P., Petrusz P. Immunocytochemical localization of beta-endorphin-containing neurons in the rat brain. Neuroendocrinology. 33:1981;28-42.
18. Fleckenstein A.E., Metzger R.R., Wilkins D.G., Gibb J.W., Hanson G.R. Rapid and reversible effects of methamphetamine on dopamine transporters. J Pharm Exp Ther. 282:1997;834-838.
19. Fleckenstein A.E., Gibb J.W., Hanson G.R. Differential effects of stimulants on monoaminergic transporters pharmacological consequences and implications for neurotoxicity . Eur J Pharmacol. 406:2000;1-13.
20. Frey K., Kilbourn M., Robinson T. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. Eur J Pharmacol. 334:1997;273-279.
21. Frey K.A., Koeppe R.A., Kilbourn M.R. Imaging of vesicular monoamine transporter. Calne D., Calne S. Parkinson's disease: advances in neurology. 2001;237-247 Lippincott Williams & Wilkins, Philadelphia, PA.
22. Friedman S.D., Castaneda E., Hodge G.K. Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity. Pharm Biochem Behav. 61:1998;35-44.
23. Fumagalli F., Gainetdinov R.R., Valenzano K.J., Caron M.G. Role of dopamine transporter in methamphetamine-induced neurotoxicity evidence from mice lacking the transporter . J Neurosci. 18:1998;4861-4869.
24. Fukumura M., Cappon G.D., Pu C., Broening H.W., Vorhees C.V. A single dose of methamphetamine-induced neurotoxicity in rats effects on neostriatal monoamines and glial fibrillary acidic protein . Brain Res. 806:1998;1-7.
25. Gainetdinov R.R., Jones R.R., Fumagalli F., Wightman R.M., Caron M.G. Re-evaluation of the role of the dopamine transporter in dopamine synthesis homeostasis. Brain Res Rev. 26:1998;148-153.
26. Gainetdinov R.R., Caron M.G. Monoamine transporters from genes to behavior . Annu Rev Pharmacol Toxicol. 43:2003;261-284.
27. Giambalvo C.T. Protein kinase C and dopamine transport -1 effects of amphetamine in vivo . Neuropharmacology. 31:1992;1201-1210.
28. Giambalvo C.T. Protein kinase C and dopamine transport-2 effects of amphetamine in vitro . Neuropharmacology. 31:1992;1211-1222.
29. Gordon I., Weizman R., Rehavi M. Modulatory effects of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol. 298:1996;27-30.
30. Guilarte T.R., Kuhlmann A.C., O'Callaghan J.P., Miceli R.C. Enhanced expression of peripheral benzodiazepine receptors in trimethyltin-exposed rat brain a biomarker of neurotoxicity . Neurotoxicology. 16:1995;441-450.
31. Harvey D.C., Lacan G., Tanious S.P., Melega W.P. Recovery of methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss. Brain Res. 871:2000;259-270.
32. Hirata H., Cadet J.L. p53-knockout mice are protected against long-term effects of methamphetamine on dopaminergic terminals and cell bodies. J Neurochem. 69:1997;780-790.
33. Hogan K.A., Staal R.G.W., Sonsalla P.K. Analysis of VMAT2 binding after methamphetamine or MPTP treatment disparity between homogenates and vesicle preparations . J Neurochem. 74:2000;2217-2220.
34. Jaber M., Dumartin B., Sage C., Haycock J.W., Roubert C., Giros B., Bloch B., Caron M.G. Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter. Eur J Neurosci. 11:1999;3499-3511.
35. Jones S.R., Gainetdinov R.R., Jaber M., Giros B., Wightman R.M., Caron M.G. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci USA. 95:1998;4029-4034.
36. Khachaturian H., Watson S.J. Some perspectives on monoamine-opioid peptide interaction in rat central nervous system. Brain Res Bull. 9:1982;441-462.
37. 18F]-GBR-13119 binding to the dopamine uptake site. Eur J Pharmacol. 216:1992;109-112.
38. Kokoshka J.M., Vaughan R.A., Hanson G.R., Fleckenstein A.E. Nature of methamphetamine-induced rapid and reversible changes in dopamine transporters. Eur J Pharmacol. 361:1998;269-275.
39. Kokoshka J.M., Metzger R.R., Wilkins D.G., Gibb J.W., Hanson G.R., Fleckenstein A.E. Methamphetamine treatment rapidly inhibits serotonin, but not glutamate transporters in rat brain. Brain Res. 799:1998;78-83.
40. Kozel, N (1997) Epidemiological trends in drug abuse, Vol. 1. National Institute on Drug Abuse. NIH publication no. 97-4204.
41. Kuhn D.M. Tryptophan hydroxylase regulation. Drug-induced modifications that alter serotonin neuronal function. Adv Exp Med Biol. 467:1999;19-27.
42. Kuhn D.M., Arthur R. Jr. Dopamine inactivates tryptophan hydroxylase and forms a redox-cycling quinoprotein possible endogenous toxin to serotonin neurons . J Neurosci. 18:1998;7111-7117.
43. Kuhn D.M., Arthur R. Jr, Thomas D.M., Elferink L.A. Tyrosine hydroxylase is inactivated by catechol-quinones and converted to redox-cycling quinoprotein possible relevance to Parkinson's disease . J Neurochem. 73:1999;1309-1317.
44. Kuhlmann A.C., Guilarte T.R. Regional and temporal expression of peripheral benzodiazepine receptor in MPTP neurotoxicity. Toxicol Sci. 48:1999;107-116.
45. Kuhlmann A.C., Guilarte T.R. Cellular and subcellular localization of peripheral benzodiazepine receptors after trimethyltin neurotoxicity. J Neurochem. 74:2000;1694-1704.
46. Langston J.W., Ballard P.A., Tetrud J.W., Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
47. LaVoie M., Hastings T.G. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine evidence against a role of extracellular dopamine . J Neurosci. 19:1999;1484-1491.
48. Law P.Y., Loh H.H., Li C.H. Properties and location of β-endorphin receptor in rat brain. Proc Natl Acad Sci USA. 76:1979;5455-5459.
49. Lee C.S., Samii A., Sossi V., Ruth T.J., Schulzer M., Holden J.E., Wudel J., Pal P.K., de la Fuente-Fernandez R., Calne D.B., Stoessl A.J. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol. 47:2000;493-503.
50. Lindblom J., Kask A., Hagg E., Harmark L., Bergstrom L., Wikberg J. Chronic infusion of a melanocortin receptor agonist modulates dopamine receptor binding in the rat brain. Pharmacol Res. 45:2002;119-124.
51. Lorez H. Fluorescence histochemistry indicates damage of striatal dopamine nerve terminals in rats after multiple doses of methamphetamine. Life Sci. 28:1981;911-916.
52. Lovick T.A. Influence of the dorsal and median raphe nuclei on neurons in the periaqueductal gray matter role of 5-hydroxytryptamine . Neuroscience. 59:1994;993-1000.
53. 11C]-WIN35, 428 . J Neurosci. 18:1998;8417-8422.
54. Melega W.P., Raleigh M.J., Stout D.B., Lacan G., Huang S.-C., Phelps M.E. Recovery of striatal dopamine function after acute amphetamine and methamphetamine-induced neurotoxicity in the vervet monkey. Brain Res. 766:1997;113-120.
55. Melikian H.E., Buckley K.M. Membrane trafficking regulates the activity of the human dopamine transporter. J Neurosci. 19:1999;7699-7710.
56. Miczek K.A., Nikulina E., Kream R.M., Carter G., Espejo E.F. Behavioral sensitization to cocaine after a brief social defeat stress c-fos expression in the PAG . Psychopharmacology. 141:1999;225-234.
57. Miller G.W., Erickson J.D., Perez J.T., Penland S.N., Mash D.C., Rye D.B., Levey A.I. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's Disease. Exp Neurol. 156:1999;138-148.
58. Naudon L., Leroux-Nicollet I., Costentin J. Short-term treatments with haloperidol or bromocriptine do not alter the density of the monoamine vesicular transporter in the substantia nigra. Neurosci Lett. 173:1994;1-4.
59. Nohtomi A., Itoh M., Yufu N., Fukahori M., Kawasaka H. Monoaminergic regulation of the levels of β-endorphin-like immunoreactivity (β-ENDi) in rat hypothalamic nuclei. Neuropeptides. 13:1989;285-289.
60. Norton W.T., Aquino D.A., Hozumi I., Chiu F.C., Brosnan C.F. Quantitative aspects of reactive gliosis a review . Neurochem Res. 17:1992;877-885.
61. O'Callaghan, JP, Miller, DB. (1993) Quantification of reactive gliosis as an approach to neurotoxicity assessment. In: Assessing neurotoxicity of drug abuse. National Institute on Drug Research Monograph Series #136, 188-212.
62. O'Callaghan J.P., Jensen K.F., Miller D.B. Quantitative aspects of drug and toxicant-induced astrogliosis. Neurochem Int. 26:1995;115-124.
63. O'Callaghan, JP, Miller, DB (2002) Neurotoxic effects of substituted amphetamines in rats and mice: challenges to the current dogma. In: Handbook of neurotoxicology (Massaro EJ, ed), pp 269-301. Totowa, NJ: Humana Press Inc.
64. O'Dell S.J., Weihmuller F.B., Marshall J.F. Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity. Brain Res. 564:1991;256-260.
65. Ricaurte G.A., Schuster C.R., Seiden L.S. Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain a regional study . Brain Res. 193:1980;153-163.
66. Ricaurte G.A., Guillery R.W., Seiden L.S., Schuster C.R., Moore R.Y. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res. 235:1982;93-103.
67. Ricaurte G.A., Seiden L.S., Schuster C.R. Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers. Brain Res. 303:1984;359-364.
68. Robinson M.B. Regulated trafficking of neurotransmitter transporters common notes but different melodies . J Neurochem. 80:2002;1-11.
69. Ryan L.J., Linder J.C., Martone M.E., Groves P.M. Histological and ultrastructural evidence that d-amphetamine causes degeneration of neostriatum and frontal cortex of rats. Brain Res. 518:1990;67-77.
70. 3H]-mazindol labeling of dopamine transporter in rat nucleus accumbens. Eur J Pharmacol. 203:1991;141-144.
71. Sonsalla P.K., Jochnowitz N.D., Zeevalk G.D., Oostveen J.A., Hall E.D. Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Res. 738:1996;172-175.
72. Stratakis C.A., Mitsiades N.S., Chrousos G.P., Margioris A.N. Dopamine affects the in vitro basal secretion of rat placental opioids in an opioid and dopamine receptor type-specific manner. Eur J Pharmacol. 315:1996;53-58.
73. Tanaka M., Nagashima K., McAllen R.M., Kanosue K. Role of the medullary raphe in thermoregulatory vasomotor control in rats. J Physiol. 540:2002;657-664.
74. Vander Borght T., Kilbourne M., Desmond T., Kuhl D., Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol. 294:1995;577-583.
75. 11C]-WIN 35,428 positron emission tomography studies and direct in vitro determinations . J Neurosci. 18:1998;419-427.
76. Volkow N.D., Chang L., Wang G.-J., Fowler J.S., Franceschi D., Sedler M., Gatley S.J., Miller E., Hitzemann R., Ding Y.-S., Logan J. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci. 21:2001;9414-9418.
77. Wagner G.C., Ricaurte A., Seiden L.S., Schuster C.R., Miller R.J., Westley J. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 181:1980;151-160.
78. Wang J.B., Moriwaki A., Uhl G.R. Dopamine transporter cysteine mutants second extracellular loop cysteines are required for transporter expression . J Neurochem. 64:1995;1416-1419.
79. Whitworth T.L., Herndon L.C., Quick M.W. Psychostimulants differentially regulate serotonin transporter expression in thalamocortical neurons. J Neurosci. 21:2001;RC192.
80. Widdowson P.S., Griffiths E.C., Slater P. Body temperature effects of opioids administered into the periaqueductal grey area of rat brain. Reg Peptides. 7:1983;259-267.
81. Wiener H.L., Hashim A., Lajtha A., Sershen H. Chronic L-deprenyl-induced up-regulation of the dopamine uptake carrier. Eur J Pharmacol. 163:1989;191-194.
82. Wilson J.M., Kalasinsky K.S., Levey A.I., Bergeron C., Reiber G., Anthony R.M., Schmunk G.A., Shannak K., Haycock J.W., Kish S.J. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med. 2:1996;699-703.
83. Wilson J.M., Levey A.L., Rajput A., Ang L., Guttman M., Shannak K., Niznik H.B., Hornykiewicz O., Pifl C., Kish S.J. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology. 47:1996;718-726.
84. Zhou D., Huether G., Wiltfang J., Hajak G., Ruther E. Serotonin transporter in the rat frontal cortex lack of circadian rhythmicity but down-regulation by food restriction . J Neurochem. 67:1996;656-661.